-+ 0.00%
-+ 0.00%
-+ 0.00%

Akeso Opens Global Phase II Trial of Ivonescimab in First-Line Kidney Cancer

PUBT·10/19/2026 12:16:13
Listen to the news
Akeso Opens Global Phase II Trial of Ivonescimab in First-Line Kidney Cancer
  • Akeso and Summit Therapeutics announced an international Phase II trial in previously untreated advanced clear cell kidney cancer on Oct. 19, 2026.
  • The study will assess ivonescimab alone or combined with cadonilimab or ipilimumab, against standard treatment with nivolumab and ipilimumab.
  • Future results will evaluate efficacy and safety; earlier studies showed promising antitumor activity with manageable safety profiles for ivonescimab and cadonilimab.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN75207) on October 19, 2026, and is solely responsible for the information contained therein.